NCT03430882View on ClinicalTrials.gov

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2018

Primary Completion Date

June 8, 2022

Study Completion Date

June 8, 2022

Conditions

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm

Interventions

DRUG

Carboplatin

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Sapanisertib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03430882 - Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors | Biotech Hunter | Biotech Hunter